Press Releases

Cordell W. Hull Joins Gilead Sciences Board of Directors

Foster City, CA -- April 18, 2001

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Cordell W. Hull has been appointed to the company's Board of Directors. Mr. Hull also will chair the Audit Committee of the Board of Directors.

Mr. Hull, 67, is the co-founder, Chairman and CEO of InfrastructureWorld, Inc., a business-to-business portal for the global infrastructure community. Prior to founding InfrastructureWorld, Inc., he has held the positions of Chairman of Bechtel Enterprises, Chief Financial Officer of Bechtel Group and President of American Express Company's merchant banking operations in London. Mr. Hull serves as a Director of Darby Overseas Investments, Ltd., Bechtel Group, Inc., Bechtel Enterprises and the Fremont Group.

"We are pleased to welcome Cordell to the Gilead Sciences Board of Directors," said James M. Denny, Chairman of Gilead's Board of Directors. "His broad business experience and financial expertise will be of great benefit as Gilead moves toward profitability with the anticipated launch of tenofovir DF, Gilead's investigational treatment for HIV infection."

Gilead Sciences
Gilead Sciences, Inc., headquartered in Foster City, CA, is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal and bacterial infections) and cancer. Gilead maintains research, development or manufacturing facilities in Foster City, CA; Boulder, CO; San Dimas, CA; Cambridge, UK and Dublin, Ireland and sales and marketing organizations in the United States, Europe and Australia.

# # #

For more information on Gilead Sciences, please visit the company's Web site at or call the Gilead Corporate Communications Department at 1-800-GILEAD-5 (1-800-445-3235).